FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of ADC Therapeutics

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

24-Jun-2015 - ADC Therapeutics Sarl announced the appointment of Dr. Chris Martin as its Chief Executive Officer.Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of Astra Zeneca in ...

appointments

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials

20-May-2014 - ADC Therapeutics (ADCT announced that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca. This follows the October 2013 announcement in which MedImmune entered into a collaboration ...

AstraZeneca MedImmune prostate cancer

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

17-Jul-2013 - ADC Therapeutics Sarl and BZL Biologics LLC announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers. PSMA is a cell-surface antigen on prostate cancer cells, and PSMA levels correlate directly with an aggressive, metastasizing ...

antibodies drug development prostate cancer

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D

19-Jul-2012 - ADC Therapeutics (ADCT) announced the appointment of former Genmab Vice President Dr Patrick van Berkel as Senior Vice President, Research & Development. Dr van Berkel has more than twenty years’ experience in the biotech industry, and in particular in developing antibody based therapeutics. He ...

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

10-Jul-2012 - Cancer Research Technology (CRT) and ADC Therapeutics Sarl (ADCT) announced that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.ADCs are an exciting and clinically ...

antibodies cancer